MX2010002820A - Analogos de tiazolidindiona para tratamiento de hipertension. - Google Patents
Analogos de tiazolidindiona para tratamiento de hipertension.Info
- Publication number
- MX2010002820A MX2010002820A MX2010002820A MX2010002820A MX2010002820A MX 2010002820 A MX2010002820 A MX 2010002820A MX 2010002820 A MX2010002820 A MX 2010002820A MX 2010002820 A MX2010002820 A MX 2010002820A MX 2010002820 A MX2010002820 A MX 2010002820A
- Authority
- MX
- Mexico
- Prior art keywords
- hypertension
- treatment
- halo
- aliphatic
- thiazolidinedione analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invenci?n se refiere a an?logos de triazolidindiona que son ?tiles para el tratamiento de hipertensi?n, diabetes, y enfermedades inflamatorias. F?rmula (I), en donde: cada uno de R1 y R4 se selecciona independientemente de H, halo, alif?tico, y alcoxi, en donde el alif?tico y alcoxi son opcionalmente sustituidos con 1-3 de halo; R2 es halo, hidroxi, o alif?tico opcionalmente sustituido, y R'2 es H, o R2 y R'2 conjuntamente forman oxo; R3 es H; y El Anillo A es fenilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97263907P | 2007-09-14 | 2007-09-14 | |
PCT/US2008/010723 WO2009038681A1 (en) | 2007-09-14 | 2008-09-15 | Thiazolidinedione analogues for the treatment of hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010002820A true MX2010002820A (es) | 2010-04-01 |
Family
ID=40239575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010002820A MX2010002820A (es) | 2007-09-14 | 2008-09-15 | Analogos de tiazolidindiona para tratamiento de hipertension. |
Country Status (16)
Country | Link |
---|---|
US (1) | US8067450B2 (es) |
EP (1) | EP2203433B1 (es) |
JP (1) | JP5371988B2 (es) |
KR (1) | KR101537830B1 (es) |
CN (1) | CN101848901B (es) |
AU (1) | AU2008301905B2 (es) |
BR (1) | BRPI0817096B8 (es) |
CA (1) | CA2699289C (es) |
ES (1) | ES2398313T3 (es) |
HK (1) | HK1146484A1 (es) |
IL (1) | IL204440A (es) |
MX (1) | MX2010002820A (es) |
NZ (2) | NZ583889A (es) |
PL (1) | PL2203433T3 (es) |
RU (1) | RU2486179C2 (es) |
WO (1) | WO2009038681A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008011872A (es) | 2006-03-16 | 2009-02-10 | Metabolic Solutions Dev Compan | Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. |
UA96441C2 (ru) | 2006-03-16 | 2011-11-10 | Метаболик Солюшнз Девелопмент Компани | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением |
US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
CN101848901B (zh) | 2007-09-14 | 2012-11-21 | 新陈代谢解决方案开发公司 | 用于治疗高血压的噻唑烷二酮类似物 |
US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
WO2010105048A1 (en) * | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
AU2014202074B2 (en) * | 2009-12-15 | 2016-01-07 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
WO2011084456A1 (en) * | 2009-12-15 | 2011-07-14 | Metabolic Solutions Development Company | Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases |
KR20120092714A (ko) * | 2009-12-15 | 2012-08-21 | 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 | 비만 및 다른 대사성 질환의 치료를 위한 ppar 절약형 티아졸리딘디온 및 복합제 |
DK2513070T3 (en) * | 2009-12-15 | 2018-01-22 | Cirius Therapeutics Inc | PPAR-sparing thiazolidinedione salts for the treatment of metabolic disorders |
NZ600421A (en) * | 2009-12-15 | 2014-06-27 | Metabolic Solutions Dev Co Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
NZ602883A (en) | 2010-04-19 | 2014-09-26 | Metabolic Solutions Dev Co Llc | Novel synthesis for thiazolidinedione compounds |
WO2011133611A1 (en) * | 2010-04-21 | 2011-10-27 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
KR101857307B1 (ko) | 2010-08-10 | 2018-05-11 | 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 | 티아졸리딘디온 화합물의 합성법 |
MX349006B (es) * | 2010-08-10 | 2017-07-06 | Cirius Therapeutics Inc | Nueva sintesis para compuestos de tiazolidindiona. |
WO2012109495A1 (en) * | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
WO2012149083A1 (en) * | 2011-04-28 | 2012-11-01 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones for the treatment of kidney related diseases |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
US8969581B2 (en) | 2013-03-14 | 2015-03-03 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
HUE050549T2 (hu) | 2013-07-22 | 2020-12-28 | Metabolic Solutions Dev Co Llc | PPAR-kímélõ vegyületek metabolikus betegségek kezelésére |
EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
WO2019154958A1 (en) | 2018-02-08 | 2019-08-15 | Enyo Pharma | Use of modulators of neet proteins for the treatment of infection |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
WO1986002073A1 (en) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
CZ196693A3 (en) | 1991-04-11 | 1994-05-18 | Upjohn Co | Thiazolidinedione derivatives, and process for preparing thereof |
NO302471B1 (no) * | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
NO305987B1 (no) * | 1994-04-11 | 1999-08-30 | Sankyo Co | Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
IL118778A (en) | 1995-07-03 | 1999-07-14 | Sankyo Co | Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor |
WO2000066102A2 (en) * | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
WO2001000579A1 (en) | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
SK14452003A3 (sk) | 2001-04-26 | 2004-04-06 | Liva, A. S. | Spôsob výroby pioglitazonu ako antidiabetika |
WO2003026586A2 (en) * | 2001-09-28 | 2003-04-03 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
ATE372336T1 (de) | 2002-07-16 | 2007-09-15 | Cadila Healthcare Ltd | Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen |
WO2004082715A1 (ja) * | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
US7230016B2 (en) | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
JP2005015477A (ja) * | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
WO2005021542A2 (en) * | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Process for the preparation of pioglitazone |
AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
ES2393197T3 (es) | 2004-09-28 | 2012-12-19 | Otsuka Pharmaceutical Co., Ltd. | Compuesto de carbostirilo |
JP2009530293A (ja) | 2006-03-16 | 2009-08-27 | メタボリック ソリューションズ ディベロップメント カンパニー | チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法 |
UA96441C2 (ru) | 2006-03-16 | 2011-11-10 | Метаболик Солюшнз Девелопмент Компани | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением |
MX2008011872A (es) | 2006-03-16 | 2009-02-10 | Metabolic Solutions Dev Compan | Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. |
CN101848901B (zh) | 2007-09-14 | 2012-11-21 | 新陈代谢解决方案开发公司 | 用于治疗高血压的噻唑烷二酮类似物 |
WO2010105048A1 (en) | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
-
2008
- 2008-09-15 CN CN2008801147383A patent/CN101848901B/zh active Active
- 2008-09-15 NZ NZ583889A patent/NZ583889A/en unknown
- 2008-09-15 WO PCT/US2008/010723 patent/WO2009038681A1/en active Application Filing
- 2008-09-15 KR KR1020107008064A patent/KR101537830B1/ko active IP Right Grant
- 2008-09-15 BR BRPI0817096A patent/BRPI0817096B8/pt active IP Right Grant
- 2008-09-15 MX MX2010002820A patent/MX2010002820A/es active IP Right Grant
- 2008-09-15 NZ NZ597381A patent/NZ597381A/xx unknown
- 2008-09-15 JP JP2010524882A patent/JP5371988B2/ja active Active
- 2008-09-15 RU RU2010114727/04A patent/RU2486179C2/ru active
- 2008-09-15 US US12/677,541 patent/US8067450B2/en active Active
- 2008-09-15 EP EP08832210A patent/EP2203433B1/en active Active
- 2008-09-15 CA CA2699289A patent/CA2699289C/en active Active
- 2008-09-15 ES ES08832210T patent/ES2398313T3/es active Active
- 2008-09-15 AU AU2008301905A patent/AU2008301905B2/en active Active
- 2008-09-15 PL PL08832210T patent/PL2203433T3/pl unknown
-
2010
- 2010-03-11 IL IL204440A patent/IL204440A/en active IP Right Grant
-
2011
- 2011-01-21 HK HK11100608.1A patent/HK1146484A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2203433B1 (en) | 2012-10-31 |
RU2486179C2 (ru) | 2013-06-27 |
CN101848901A (zh) | 2010-09-29 |
NZ597381A (en) | 2013-03-28 |
NZ583889A (en) | 2012-01-12 |
CA2699289A1 (en) | 2009-03-26 |
AU2008301905B2 (en) | 2013-06-27 |
AU2008301905A1 (en) | 2009-03-26 |
WO2009038681A1 (en) | 2009-03-26 |
JP5371988B2 (ja) | 2013-12-18 |
KR101537830B1 (ko) | 2015-07-17 |
ES2398313T3 (es) | 2013-03-15 |
PL2203433T3 (pl) | 2013-04-30 |
HK1146484A1 (en) | 2011-06-10 |
RU2010114727A (ru) | 2011-10-20 |
CN101848901B (zh) | 2012-11-21 |
JP2010539171A (ja) | 2010-12-16 |
BRPI0817096A8 (pt) | 2017-10-10 |
BRPI0817096B8 (pt) | 2021-05-25 |
IL204440A (en) | 2013-05-30 |
CA2699289C (en) | 2016-01-19 |
BRPI0817096B1 (pt) | 2020-11-10 |
US8067450B2 (en) | 2011-11-29 |
US20100222399A1 (en) | 2010-09-02 |
BRPI0817096A2 (pt) | 2017-05-02 |
KR20100075915A (ko) | 2010-07-05 |
EP2203433A1 (en) | 2010-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010002820A (es) | Analogos de tiazolidindiona para tratamiento de hipertension. | |
MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
WO2009016462A3 (en) | Substituted bicyclolactam compounds | |
CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
MY147390A (en) | Substituted isoindoles as bace inhibitors and their use | |
PH12013500745A1 (en) | Azaadamantane derivatives and methods of use | |
NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
EA200601295A1 (ru) | Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета | |
MX2009003821A (es) | Compuestos de n-aril pirazol para usarse contra la diabetes. | |
IN2012DN00869A (es) | ||
WO2007103550A3 (en) | Substituted aminothiazole derivatives with anti-hcv activity | |
UA85707C2 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
MY149070A (en) | 1h-quinazoline-2,4-diones | |
TW200700069A (en) | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
NZ581438A (en) | Kallikrein 7 modulators | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
TW200740827A (en) | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | |
HK1159614A1 (en) | Caspase inhibitors and uses thereof | |
MX2010008226A (es) | Derivados de difluorobifenilamida para el tratamiento de hipertension ocular. | |
TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
MX2008012424A (es) | Proceso convergente para la sintesis de derivados de taxanos. | |
TW200613292A (en) | Benzothiazolium compounds | |
TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |